Structure via PubChem · Public domain (PubChem)
pridopidine
Sign in to saveAlso known as 4-[3-(methanesulfonyl)phenyl]-1-propylpiperidine
Pridopidine (developmental code name PL-101) is an orally administrated small molecule investigational drug. Pridopidine is a selective and potent sigma-1 receptor agonist. It is being developed by Prilenia Therapeutics and is currently in late-stage clinical development for Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS).
Chemical data
- Formula
- C15H23NO2S
- Molecular weight
- 281.4 g/mol
- IUPAC name
- 4-(3-methylsulfonylphenyl)-1-propylpiperidine
- SMILES
- CCCN1CCC(CC1)C2=CC(=CC=C2)S(=O)(=O)C
- InChIKey
- YGKUEOZJFIXDGI-UHFFFAOYSA-N
- XLogP
- 2.6
- Polar surface area
- 45.8 Ų
- H-bond donors
- 0
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- amyotrophic lateral sclerosis, Parkinson disease, Huntington disease
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 281.145
- Has use
- medication
Show 3 more facts
- chemical formula
- C₁₅H₂₃NO₂S
- World Health Organisation international non-proprietary name
- بريدوبيدين
- canonical SMILES
- CCCN1CCC(CC1)C2=CC(=CC=C2)S(=O)(=O)C
Sources (2)
via Wikidata · CC0
~5 min read
Encyclopedic overview
10 sectionsContents
- Mechanism of action
- Chemistry
- Analogues
- Potential indications
- Huntington's disease
- Amyotrophic lateral sclerosis
- Society and culture
- Legal status
- See also
- References
Pridopidine (developmental code name PL-101) is an orally administrated small molecule investigational drug. Pridopidine is a selective and potent sigma-1 receptor agonist. It is being developed by Prilenia Therapeutics and is currently in late-stage clinical development for Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS).
== Mechanism of action == Pridopidine works by binding and activating an intracellular protein called the sigma-1 receptor (S1R) located at the mitochondria-associated membrane (MAM) of the endoplasmic reticulum. The S1R regulates key cellular processes crucial to neuronal health and survival. Selective activation of the S1R is a promising therapeutic target for treating neurodegenerative and neurodevelopmental disorders.
Excerpted from Wikipedia’s “pridopidine” article, available under the CC BY-SA 4.0 licence.